Emerging data from Phase 1b study of RLYB212 shows rapid and complete elimination of transfused HPA-1a positive platelets Phase 1 study of RLYB116 ongoing; initial single dose safety, PK, and PD data expected for the 30 mg dose in the 4Q 2022
Farmington-born biotech Rallybio to go public in $100M IPO hartfordbusiness.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hartfordbusiness.com Daily Mail and Mail on Sunday newspapers.
By Natalie Missakian
Just 10 months after Rallybio launched in early 2018, Fierce Biotech, an international trade journal widely followed in the bioscience world, dubbed it one of the year’s 15 most promising biotechs.
The New Haven-based company had yet to make any groundbreaking discoveries. In fact, it didn’t have a single drug in its portfolio. And outside of its announced focus on treatments for severe rare diseases, Rallybio’s founders had offered few details about what medical conditions the startup planned to pursue.
Still, the company was getting noticed not only by reporters covering the industry but also by investors as evidenced by the $37 million it raised shortly after setting up its first lab and office at UConn’s Technology Incubation Program (TIP) in Farmington.